Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 11,256 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Propionic Acidemia
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Duchenne Muscular Dystrophy
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Advanced Nonhaematologic Malignancies
Interventions: BOS172738; Drug
Lead sponsor: Boston Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution; Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Irvine, California • Centennial, Colorado • North Palm Beach, Florida + 13 more

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 0 Years to 6 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more

Conditions: Dermatitis, Atopic
Interventions: Gel Cream; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Adrenal Hyperplasia, Congenital
Interventions: Not listed
Lead sponsor: Office of Rare Diseases (ORD); NIH
Eligibility: 20 Years to 35 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Total Parenteral Nutrition, Necrotizing Enterocolitis of Newborn
Interventions: Similac Probiotic Tri-Blend; Dietary Supplement
Lead sponsor: Pediatrix; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Mesa, Arizona • Phoenix, Arizona

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 21 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sickle Cell Disease
Interventions: Single Session Problem-Solving Intervention; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Lomecel-B medicinal signaling cells; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: Up to 12 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Adult Spinal Deformity
Interventions: Not listed
Lead sponsor: AO Foundation, AO Spine; Other
Eligibility: 60 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 5
States / cities: San Francisco, California • Minneapolis, Minnesota • St Louis, Missouri + 2 more

Conditions: Biliary Atresia
Interventions: Intravenous immunoglobulin (IVIG); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Days to 120 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, TT vaccine booster; Drug · Biological
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 58
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more

Conditions: Neonatal Abstinence Syndrome
Interventions: Methadone; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 1 Month
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Dystrophic Epidermolysis Bullosa
Interventions: Granulocyte Colony Stimulating Factor (GCSF); Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Congenital Diaphragmatic Hernia
Interventions: Fetoscopic Endoluminal Tracheal Occlusion (FETO) Procedure; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Limb-Girdle Muscular Dystrophy, Type 2E
Interventions: SRP-9003; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 15 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sickle Cell Disease
Interventions: Placebo, HQK-1001; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 8
States / cities: Madison, Alabama • Oakland, California • Daytona Beach, Florida + 5 more

Conditions: Turner Syndrome
Interventions: Lonapegsomatropin, Somatropin; Biological · Drug
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 1 Year to 10 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 19
States / cities: Palo Alto, California • San Diego, California • Aurora, Colorado + 16 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions: aldesleukin, recombinant interferon alfa, sargramostim; Biological
Lead sponsor: Cancer Treatment Centers of America; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Zion, Illinois

Conditions: Becker Muscular Dystrophy, Duchenne Muscular Dystrophy
Interventions: Gentamicin; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Ren-Nu and KetoCitra; Dietary Supplement
Lead sponsor: Richard Fatica; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Review of Charts From Amish/Mennonite Variant PA Patients

Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Phase 2/3 Study of IGSC, 20% in PIDD

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area

Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia

Probiotics/TPN in the NICU

Infant Medical Records: Case Report Proposal

Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Prospective Evaluation of Elderly Deformity Surgery

Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

Safety and Efficacy of Fetoscopic Endoluminal Tracheal Occlusion in Congenital Diaphragmatic Hernia

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

Gentamicin Treatment of Muscular Dystrophy

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease